Psoriatic Arthritis

In addition to swollen joint count, joint location and functional impairment should also be considered when describing psoriatic arthritis as moderate.

Data from the COSMOS study showed that 44.4% of patients who received guselkumab versus 19.8% of patients who received placebo achieved a ≥20% improvement at week 24.

Rheumatology Network interviewed Laura Coates, MBChB, MRCP, PhD, to discuss what her recent study adds to existing psoriatic arthritis (PsA) research, what some of the key factors are that impact a patient’s opinion of remission, and the clinical significance.

Catch up on Rheumatology Network's most recent highlights in psoriatic arthritis news.

For patients with psoriatic arthritis (PsA), multidomain disease was associated with worse measures of disease activity, quality of life, and work productivity.

Investigators utilized study data to further investigate the concept of patient-defined remission and identify which factors were associated with patient-defined remission or low disease activity.

A combination of adalimumab (ADA) treatment and patient support programs (PSPs) may reduce opioid use and increase medication adherence.

Patients with psoriatic arthritis and minimal disease activity who continued ixekizumab therapy fared significantly better than those who stopped using the drug, including fewer relapses related to disease activity.

A recent study explores the correlation between work obligations and anxiety in patients with inflammatory rheumatic diseases during the second wave of the COVID-19 pandemic. Poor quality of life due to self-isolation has been reported in this patient population.

"Our results suggest that there are likely to be certain treatments that will confer preferential response in psoriatic arthritis (PsA), including tumor necrosis factor (TNF) inhibitors and IL-17 medications, compared to other options," stated Jeffrey Curtis, MD.

In today’s episode of Overdrive by Rheumatology Network, we sat down with Philip J. Mease, MD, to discuss his study, “Comparative effectiveness of guselkumab in psoriatic arthritis: results from systematic literature review and network meta-analysis.”

Catch up on Rheumatology Network's most recent highlights in psoriatic arthritis news.

Patients with oligoarticular psoriatic arthritis (PsA) receiving apremilast monotherapy fared better than those who initiated methotrexate (MTX) therapy or biologic disease-modifying antirheumatic drug (bDMARD) initiators.

While men with inflammatory arthritis drink significantly more alcohol and have less severe disease activity, alcohol is not linked to disease remission.

Investigators observed that patients treated with secukinumab were more likely to achieve Psoriasis Area Severity Index (PASI) 75/90/100 responses and Investigator’s Global Assessment (IGA) improvement at 52 weeks than those administered usetkinumab, regardless of their psoriatic arthritis (PsA) status.

This week, Rheumatology Network sat down with Philip J. Mease, MD, to discuss his study, “Comparative effectiveness of guselkumab in psoriatic arthritis: results from systematic literature review and network meta-analysis.”

“The sustained benefits for patients with active psoriatic arthritis across multiple domains indicate that guselkumab may offer a novel mechanism by which to provide extended improvements in the diverse manifestations of psoriatic arthritis,” Laura Coates, PhD, and team concluded.

A comparison of pooled phase 3 data showed patients treated with the IL-17A inhibitor fared better than those on ustekinumab, without influence from their PsA status.

A post-hoc analysis shows that the human monoclonal antibody was linked to sustained improvements according to different disease measurements through week 52.

A majority of studies reported a worsening of disease activity post-delivery.

Recommendations for supporting patients with psoriatic arthritis in the primary care setting and guidance on referring patients to a specialist.

Circumstances that may warrant a switch in therapy to either a similar drug or a drug of a different class.

Currently available non-biologic and biologic therapies used to treat psoriatic arthritis and guidance regarding proper treatment selection and use.

Goals of therapy and considerations that need to be factored into treatment decisions for patients with psoriatic arthritis.

An overview of the clinical manifestations of psoriatic arthritis and recommendations for properly assessing patient symptoms when measuring disease severity.